Meeting
2022 ASCO Annual Meeting
Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor.
Authors
Jason A Mouabbi
MD Anderson Cancer Center, Houston, TX
Jason A Mouabbi , Akshara Singareeka Raghavendra , Roland L. Bassett Jr., Amy Aida Hassan , Debu Tripathy , Rachel M. Layman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1067)
DOI
10.1200/JCO.2022.40.16_suppl.1067
Abstract #
1067
Poster Bd #
445
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.
First Author: Jing Shan Lim
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
First Author: Elisa Agostinetto
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges